SCHEMBL4097414

SCHEMBL4097414

Fc1ccc(-c2nc(Cl)[nH]c2-c2ccnc(F)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 19/20 0.60
MAPK13 O15264 15/20 0.60
MAPK12 P53778 15/20 0.60
MAPK11 Q15759 15/20 0.60
GCGR P47871 7/20 0.52
PRKD3 O94806 1/20 0.48
MAP4K4 O95819 1/20 0.48
FRK P42685 1/20 0.48
MAPK9 P45984 1/20 0.48
CSNK1A1 P48729 1/20 0.48
CSNK1D P48730 1/20 0.48
GSK3B P49841 1/20 0.48
PTK6 Q13882 1/20 0.48
PRKD2 Q9BZL6 1/20 0.48
CLK4 Q9HAZ1 1/20 0.48
ALOX5 P09917 1/20 0.44
BRAF P15056 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6168758 0.82 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL4090706 0.81 ADORA2B (0.57) MAPK14MAPK13MAPK12MAPK11MAP4K4
SCHEMBL3231109 0.80 MAPK14 (0.92) MAPK14MAPK13MAPK12MAPK11GSK3B
SCHEMBL4462251 0.75 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11GSK3B
SCHEMBL4105858 0.75 MAPK13 (0.60) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL828294 0.75 MAPK14 (0.74) MAPK14MAPK13MAPK12MAPK11
SCHEMBL4466879 0.73 MAPK14 (0.94) MAPK14MAPK13MAPK12MAPK11GSK3B
SCHEMBL4097997 0.73 MAPK14 (0.68) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL828544 0.73 MAPK14 (0.55) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL4457807 0.72 MAPK14 (0.91) MAPK14MAPK13MAPK12MAPK11GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION 2009-08-27 US disclosed
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION 2009-08-27 US disclosed
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION 2009-08-27 US disclosed
US-20060106020-A1 Tetracyclic inhibitors of Janus kinases INCYTE CORPORATION 2006-05-18 US disclosed
WO-2005105814-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION (US) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES JAK1, JAK2, JAK3 MAPK14 136/4885MAPK13 99/4885MAPK12 111/4885
US-20060106020-A1 Tetracyclic inhibitors of Janus kinases JAK1, JAK2, JAK3 MAPK14 136/4885MAPK13 99/4885MAPK12 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.